Best Practice Models for Opioid Treatment Programs Motivated Stepped Care: An Adaptive Treatment Approach. Van L. King, MD
|
|
- Harvey Harrison
- 6 years ago
- Views:
Transcription
1 Best Practice Models for Opioid Treatment Programs Motivated Stepped Care: An Adaptive Treatment Approach Van L. King, MD UT Health, Department of Psychiatry Grand Rounds November 15, 2016
2 Addiction Treatment Services Hospital-based clinic established 1972 in southeast Baltimore Comprehensive drug abuse treatment using methadone as one component of care Census of 500 primarily opioid dependent patients typical of patients in similar community-based treatment programs Long term or indefinite length of treatment
3 Common Problems Poor adherence to treatment services Partial and poor treatment response Fixed and limited levels of service Reliance on single elements of care Staff and patient demoralization
4 Solution Improve treatment adherence Use combination of evidence-based approaches Efficient use of resources using a patient - treatment matching paradigm Expose more symptomatic patients to most experienced and trained staff
5 Definition of Adaptive Treatment Strategy Use evidence-based treatment guidelines use empirically-based interventions integrate and combine interventions match intensity/dose of service to symptom severity Use established rules to guide treatment planning initiation of treatment services changes in intensity and type of services discharge and return to treatment Use interventions to achieve good patient adherence motivational interventions behavioral incentives available social supports
6 Recognize Importance of Opioid Agonist Medications One of the most effective interventions for opioid dependence (Hazelton now endorses) Use flexible dispensing schedules and doses Integrate with other interventions to improve response Ball and Ross, 1991 McLellan et al., 1993
7 Recognize Importance of Psychotherapies Intensifying routine drug abuse counseling can reduce drug use Adding professional psychotherapies can further reduce drug use Woody et al., 1983, 1995 McLellan et al., 1993 Kidorf et al., 1999 Brooner et al., 2004
8 Recognize Importance of Behavioral Reinforcement Effective behavioral incentives will enhance reductions in drug use Kidorf et al., 1993,1999 Silverman et al., 1996 Rawson et al., 2002 Brooner et al., 2004, 2007 King & Brooner, 2007 Effective behavioral incentives will enhance attendance to counseling sessions Stitzer et al., 1977 Kidorf et al., 1994,1999 Brooner et al., 2004, 2007
9 Use Behavioral Reinforcement to Improve Treatment Adherence Methadone dosing time restrictions Methadone dose taper in preparation for discharge Rapid methadone taper reversal and/ or clinic re-admission for treatment adherence
10 Motivated Stepped Care Adaptive Treatment Model Use evidence-based treatment guidelines opioid agonist treatment cognitive behavioral therapy / motivational interventions behavioral reinforcement Use established rules to guide treatment planning adaptive stepped care treatment matching utilizing ongoing treatment outcome data step rules followed by all staff and for all patients Use interventions to achieve good adherence fully integrate evidence-based treatments supervisors and doctors lead intensified group treatment use available social supports
11 Addiction Treatment Services Program Overview New Admissions Admission Evaluation History/Physical Admit Lab Work Infectious Diseases Other Evaluation Psychiatric Other Substance Use Psychosocial Treatment Services - On Site Medications Limited Medical Care Weekly Urine Testing Counseling Weeks 1-4 Treatment Induction and Initial Stabilization Begin Motivated Stepped Care System Week 5
12 Bi-directional Motivated Stepped Care (MSC) Model Medical Maintenance Schedules 13 take-home medication doses 27 take-home medication doses indefinite duration STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks STEP individual sessions/week 8 group sessions/week 4-8 weeks Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week attendance guaranteed readmission in 24 hours
13 Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks Patients move from Step 1 to Step 2 after 2 consecutive weeks of: missed counseling sessions AND/OR drug positive urine specimens
14 Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks Patients move from Step 2 back to Step 1 if during the 4 week period they: attend all counseling for 2 consecutive weeks AND are drug negative for 2 consecutive weeks
15 Motivated Stepped Care (MSC) in Action STEP 2 1 individual session/week 2 group sessions/week 2-4 weeks STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move from Step 2 to Step 3 if during the 4 week period they produce 2 weeks of: missed counseling sessions AND/OR drug positive urine specimens
16 Motivated Stepped Care (MSC) in Action STEP 1 1 individual session wk/mo indefinite duration STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move back from Step 3 to Step 1 if during the 8 week period they: attend all counseling sessions in 4 consecutive weeks AND have drug negative urines in 4 consecutive weeks
17 Motivated Stepped Care (MSC) in Action STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Patients move from Step 3 to a medication taper and possible discharge if they do not produce over 8 weeks: Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed readmission in 24 hours 4 consecutive weeks of full counseling attendance AND 4 consecutive weeks of drug negative urine specimens
18 Motivated Stepped Care (MSC) in Action Medication taper reversed and restart Step 3 by: attending all counseling for 1 week AND submitting single drug negative urine STEP 3 1 individual session/week 8 group sessions/week 4-8 weeks Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed readmission in 24-hours
19 Motivated Stepped Care (MSC) in Action STEP 3 1 individual sessions/week 8 group sessions/week 4-8 weeks Readmission after taper in 1 to 7 days with agreement to: restart care in Step 3 AND work towards Step 1 Methadone Taper and Discharge 30-day taper to zero dose reverse taper for 1 week adherence guaranteed rapid readmission
20 Randomized and Controlled Clinical Trial Enrolled new admissions (n=144/160) Methadone induction. Completed 1 month baseline (n=127) Motivated Stepped Care (MSC) Randomized to: -or- Standard Stepped Care (SSC) STEP 1 (New Admits) N=65 STEP 1 (New Admits) N=62 STEP 2 (2-4 Weeks) STEP 2 (2-4 Weeks) STEP 3 (4-8 Weeks) Discharge STEP 3 (4-8 Weeks) Discharge Rapid Readmission Rapid Readmission Participants compared on: 90 day retention, counseling adherence/attendance, weekly drug positive urine
21 Demographic Characteristics of Sample Variable MSC SSC p Age (yrs) ns Education (yrs) ns Female 57% 52% ns Minority 60% 66% ns
22 % Completing 90 Days Randomized Care Treatment Retention
23 Weekly Counseling Adherence % Sessions Attended * * MSC SSC
24 Weekly Urinalysis Results % Positive Urine Samples * MSC SSC
25 Post-Trial Therapeutic Transfer of Controls Rescue of poor responders Pre-defined partial/poor responding Transfer to MSC treatment (35/62 = 60%) Within-subject crossover design
26 Counseling Adherence: Pre & Post Transfer (n=35) % Sessions Attended * Pre-90 days Post-90 days *
27 Urinalysis Results: Pre & Post Transfer (n=35) % Positive Urine Samples * Pre-90 days Post-90 days *
28 MSC is Powerful and Versatile Reduces cannabis use Kidorf et al., 2007 Improves involvement of family and other community supports Kidorf et al., 1997; 2007 Improves rates of employment and other productive activity Kidorf et al., 1998; 2004 As effective as voucher based protocols in decreasing drug use Brooner et al., 2007
29 Conclusions/Summary Single service and restricted care models are not adequate to treat the range of needs Severe, long-term problems benefit from adaptive, long-term treatment solutions MSC is an efficient and clinically effective approach to match the amount of treatment to objective ongoing indicators of symptom severity and treatment response
30 Be Well Clinic, UT Health Structured, multiple levels of service intensity. Can accommodate short-term and long-term treatment needs. Behaviorally integrate medication and counseling services. Utilize buprenorphine or naltrexone for opioid use. Utilize naltrexone and other medications for other drug use disorders. Utilize other reinforcers such as family, social support and legal status to assist in process of rehabilitation and recovery.
31 Thank you
32 Continuous Performance Improvement Collection and tracking of counseling attendance and urine testing data using a computer-based platform All data monitored weekly by executive staff Data monitored weekly in clinical rounds for Step 3 patients Data monitored monthly/ quarterly for reduced care patients
Opioid Treatment Program Reimbursement Re-bundling Proposal
Opioid Treatment Program Reimbursement Re-bundling Proposal Maryland Department of Health and Mental Hygiene April 22, 2016 The Department reviewed close to 50 letters and emails submitted by stakeholders
More informationTrigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module VI Counseling Buprenorphine Patients Myths About the Use of Medication in Recovery! Patients are still addicted!
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationSW OREGON OPIOID SUMMIT. Medication Assisted Recovery for Opioid Use Disorder. Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass
SW OREGON OPIOID SUMMIT Medication Assisted Recovery for Opioid Use Disorder Gregory S. Brigham, Ph.D. Adapt / SouthRiver CHC / Compass Opioid Agonists Mu (μ) receptors stimulated by opioids causing full
More informationThe Importance of Psychological Treatment and Behavioral Support
The Importance of Psychological Treatment and Behavioral Support Michael W. Otto, PhD Department of Psychological and Brain Science Boston University Conflicts and Acknowledgements No industry funding
More informationBuprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction
Buprenorphine is the most effective office-based treatment available for heroin and prescription opioid addiction The Problem The overdose death rate in Missouri and in the country has been rising for
More informationManagement Options for Opioid Dependence:
Management Options for Opioid Dependence: Policy Implications and Recommendations Dan Ollendorf, PhD Sarah Jane Reed, MSc New England CEPAC Goal: To improve the application of evidence to guide practice
More informationROSC & MAT II: Opioid Treatment Services
ROSC & MAT II: Opioid Treatment Services September 23, 2015 Stan DeKemper Executive Director Indiana Credentialing Association on Addiction and Drug Abuse 1 GOALS Review medication assisted recovery Identify
More informationImproving Outcomes in Methadone Treatment
Improving Outcomes in Methadone Treatment Cognitive/Behavioral Treatment Contingency Management Michael J. McCann, MA Matrix Institute on Addictions COMP Symposium September 11, 2007 Overview of Presentation
More information2/19/18. Today s talk. Today s talk. The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders
The Role of Behavioral Interventions in Buprenorphine Treatment of Opioid Use Disorders Roger D. Weiss, MD Chief, Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA Professor of Psychiatry,
More informationThe role of behavioral interventions in buprenorphine treatment of opioid use disorders
The role of behavioral interventions in buprenorphine treatment of opioid use disorders Roger D. Weiss, MD Harvard Medical School, Boston, MA, McLean Hospital, Belmont, MA, USA Today s talk Review of studies
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) What has changed? Effective January 16, 2018, Coordinated Care will change the requirement for form HCA 13-333 Medication
More informationSTARTING SUBOXONE IN PRIMARY CARE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences STARTING SUBOXONE IN PRIMARY CARE MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Review evidence of how to
More information7/7/2016 Journal of the American Medical Association,
1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of
More informationClinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT)
Clinical Guidelines and Coverage Limitations for Medication Assisted Treatment (MAT) For Apple Health clients served Fee-for-Service and through contracted Medicaid Managed Care Organizations Updated January
More informationDMHAS ASAM SERVICE DESCRIPTIONS
(DMHAS) Fee for Service (FFS) ANNEX A1 DMHAS ASAM SERVICE DESCRIPTIONS Please carefully review the Service Descriptions that are included in the DMHAS FFS Initiatives in this Annex A1 contract section.
More informationThe Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine. March 10, 2016
The Role of Primary Care Teams and the Medical Neighborhood in Addressing the Opioid Crisis in Maine March 10, 2016 Objectives Review current state of opioid crisis in Maine Briefly review physiology of
More informationRI Centers of Excellence for the
RI Centers of Excellence for the Treatment of Opioid Use Disorder COE CODAC Behavioral Healthcare Linda Hurley President/CEO 9-18-17 for the Warren Alpert Medical School of Brown University RI s Strategic
More informationPrescription Monitoring Program. One Agency s Experience. Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA
Prescription Monitoring Program One Agency s Experience Ron Jackson, MSW, LICSW Evergreen Treatment Services Seattle, WA Agency Description Private non-profit, founded 1973 $8.5 M annual budget; staff
More informationConfronting the Opioid Epidemic: Suboxone in Primary Care
Confronting the Opioid Epidemic: Suboxone in Primary Care Kami Harless, MD 1 The Opioid Epidemic 2 The Opioid Epidemic 3 Washington Epidemic 4 King County Epidemic 5 King County Epidemic 6 Outline Opioid
More informationBehavioral Therapies for Methamphetamine Use
Behavioral Therapies for Methamphetamine Use Will M. Aklin, PhD National Institute on Drug Abuse Division of Therapeutics and Medical Consequences June 27, 2017 1 Behavioral Therapy Development Program
More informationMedications for Opioid Use Disorder. Charles Brackett, MD, MPH General Internal Medicine, DHMC
Medications for Opioid Use Disorder Charles Brackett, MD, MPH General Internal Medicine, DHMC Opioid Related Deaths are on the Rise in the US National Vital Statistics System Mortality File Deaths are
More informationTHE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences THE UNSTABLE BUPRENORPHINE- NALOXONE PATIENT MARK DUNCAN MD UNIVERSITY OF WASHINGTON SPEAKER DISCLOSURES Any conflicts
More informationTreatment of Methamphetamine Dependence: Does Treatment Work?
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human Behavior David Geffen School of Medicine University
More informationVermont Hub and Spoke Model Treatment Need Questionnaire
Vermont Hub and Spoke Model Treatment Need Questionnaire Friday, June 30, 2017 John Brooklyn, MD Assistant Professor of Family Medicine and Psychiatry University of Vermont Burlington, Vermont Webinar
More informationTreatment of Youth Opioid Addiction: Approaches to a Modern Epidemic. What should we do with this case? Heroin Addiction History
Treatment of Youth Opioid Addiction: Approaches to a Modern Epidemic What should we do with this case? 17 M Onset prescription opioids 15, progressing to daily use with withdrawal within 8 months Onset
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More informationThe available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines
The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines Background, Objectives and Methods Systematic reviews (SRs) published by Cochrane Drugs
More informationSubstance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates
Substance Use Disorders (SUDs) and Medication Assisted Treatment (MAT) for Opiates What is MAT? Medication Assisted Treatment (MAT) is the use of medications, in addition to counseling, cognitive behavioral
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationAppendix F Federation of State Medical Boards
Appendix F Federation of State Medical Boards Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office SECTION I: PREAMBLE The (name of board) recognizes that the prevalence of addiction
More informationReferral to Treatment: Utilizing the ASAM Criteria
Referral to Treatment: Utilizing the ASAM Criteria AOAAM Essentials in Addiction Medicine October 22, 2016 East Lansing, MI Stephen A. Wyatt, DO Medical Director, Addiction Medicine Behavioral Health Service
More information6/6/2018. Objectives. Outline. Rethinking Medication Treatment for Opioid Use Disorder
Rethinking Medication Treatment for Opioid Use Disorder International Conference on Opioids June 10, 2018 Dustin Patil, MD Fellow, Addiction Psychiatry Boston Medical Center John Renner, MD Professor of
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2009 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationTREATING OPIOID ADDICTION IN HOMELESS POPULATIONS
TREATING OPIOID ADDICTION IN HOMELESS POPULATIONS Challenges and Opportunities Providing Medication Assisted Treatment (Buprenorphine) August 18, 2016 SPEAKERS TODAY Nilesh Kalyanaraman, MD, Chief Health
More informationClinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version
Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of
More informationInitiation and engagement in addiction treatment integrated into primary care: the role of gender
Initiation and engagement in addiction treatment integrated into primary care: the role of gender Alexander Y. Walley, MD, MSc Co-Authors: Kaylyn Duerfeldt, Joe Palmisano, Amy Sorensen-Alawad, Chris Chaisson,
More informationBuprenorphine as a Treatment Option for Opioid Use Disorder
Buprenorphine as a Treatment Option for Opioid Use Disorder Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction Psychiatry Brigham and Women s Hospital
More informationWhat Predicts the Successful Completion of Addiction Treatment?
What Predicts the Successful Completion of Addiction Treatment? Bushauna A Freeman -Dr. Metzger SUMR PROGRAM 2016 Philadelphia, PA August 17, 2016 Overview Background Addiction and Medication Assisted
More informationOpioid Use Disorder Treatment Initiation in Diverse Settings
Opioid Use Disorder Treatment Initiation in Diverse Settings Sarah Wakeman, MD, FASAM Medical Director, Mass General Substance Use Disorder Initiative Assistant Professor, Harvard Medical School Disclosures
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationEFFECTIVE PROGRAM PRINCIPLES MATRIX
Page 1 of 6 EFFECTIVE PROGRAM PRINCIPLES MATRIX (Portions taken from National Institute on Drug Abuse) The purpose of this Effective Program Principles Matrix is to provide a framework for bidders to describe
More informationCHAPTER 27: BEHAVIOR ANALYSIS AND TREATMENT OF DRUG ADDICTION
CHAPTER 27: BEHAVIOR ANALYSIS AND TREATMENT OF DRUG ADDICTION Fisher ch.27 Drug addiction is a very prevalent issue in the current United States society. The substance abuse treatments that are available
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationSubstance Abuse Suboxone Treatment
Substance Abuse Suboxone Treatment Program Waterbury Hospital Infectious Disease Clinic Richard Smith, LCSW Leonard Savage, Consumer Steven I. Aronin, MD FACP, Program Director Ryan White All Grantee Meeting
More informationIdentifying methadone maintenance clients at risk for poor treatment response: Pretreatment and early progress indicators
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/12897473 Identifying methadone maintenance clients at risk for poor treatment response: Pretreatment
More informationClinical Guidelines for the Pharmacologic Treatment of Opioid Use Disorder
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationVivitrol/Suboxone. Comparison Study Summary
Vivitrol/Suboxone Comparison Study Summary Lee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., & King, J. (2017). Comparative effectiveness of extended-release naltrexone versus
More informationManagement of Opioid Use Disorder in Primary Care
1 Northwest ATTC presents Management of Opioid Use Disorder in Primary Care Joseph O. Merrill, MD, MPH University of Washington Associate Professor of Medicine 4/26/2018 Today s Presenter 2 Joseph Merrill,
More informationADVANCED BEHAVIORAL HEALTH, INC. Clinical Level of Care Guidelines
The Clinical Level of Care Guidelines contained on the following pages have been developed as a guide to assist care managers, physicians and providers in making medical necessity decisions about the least
More informationOptimizing Suboxone in Opioid Addicts
Optimizing Suboxone in Opioid Addicts David Chim, D.O. Integrated Substance Abuse Programs Dept. of Psychiatry, UCLA K30 Translational Research Interest March 24, 2009 dchim@mednet.ucla.edu www.uclaisap.org
More informationEvidence-Based Practice: Psychosocial Interventions
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio Talk Outline What is an evidence-based practice?
More informationIntNSA Webinar Series
BUPRENORPHINE CLINIC: A MULTIDISCIPLINARY MODEL FOR OPIOID MAINTENANCE THERAPY Stephen Strobbe, PhD, RN, NP, PMHCNS-BC, CARN-AP Monday, June 4, 2012 IntNSA Webinar Series Funding for this webinar was made
More informationRECOMMENDATIONS FOR HEALTH CARE PROVIDERS
Ending Addiction Changes Everything RECOMMENDATIONS FOR HEALTH CARE PROVIDERS CRITICAL ADDICTION PREVENTION, TREATMENT AND MANAGEMENT SERVICES TO INCLUDE IN ROUTINE HEALTH CARE PRACTICE JULY 2013 In the
More informationOpioid Treatment in North Carolina SEPTEMBER 13, 2016
Opioid Treatment in North Carolina SEPTEMBER 13, 2016 Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2007 Source Where Respondent Obtained
More informationOpioids Research to Practice
Opioids Research to Practice CRIT Program May 2008 Daniel P. Alford, MD, MPH Associate Professor of Medicine Boston University School of Medicine Boston Medical Center 32 yo female brought in after heroin
More informationOPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION
OPIOID USE DISORDER CENTERS OF EXCELLENCE APPLICATION GENERAL INFORMATION The Department of Human Services (DHS) is implementing 50 opioid use disorder (OUD) Health Homes or Centers of Excellence (COE)
More informationMedicaid and the Opioid Crisis
Medicaid and the Opioid Crisis Erica Floyd Thomas Bureau Chief of Medicaid Policy Agency for Health Care Administration Presented to: Medical Care Advisory Committee March 20, 2018 1 Florida Medicaid Covers
More informationCounseling plus Buprenorphine Naloxone Maintenance Therapy for Opioid Dependence
The new england journal of medicine original article Counseling plus Buprenorphine Naloxone Maintenance Therapy for Opioid Dependence David A. Fiellin, M.D., Michael V. Pantalon, Ph.D., Marek C. Chawarski,
More informationSerious Mental Illness and Opioid Use Disorder
Serious Mental Illness and Opioid Use Disorder Serious Mental Illness and Opioid Use Disorders Arthur Robin Williams, MD MBE Columbia University, Department of Psychiatry Nick Szubiak, MSW, LCSW Director,
More informationPsychosocial Treatments for Opioid Use Disorder Overview
Psychosocial Treatments for Opioid Use Disorder Overview Nalan Ward, MD Director Outpatient Addiction Services Department of Psychiatry Massachusetts General Hospital *Images used for educational purposes
More informationOPIOIDS: ENGAGING PATIENTS IN OUD TREATMENT
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences OPIOIDS: ENGAGING PATIENTS IN OUD TREATMENT ADDY ADWELL, RN-BC, BSN HARBORVIEW MEDICAL CENTER GENERAL DISCLOSURES
More informationHEALTHWEST. Procedure. No Prepared by: Effective Date: April 5, 2018 Revised Date: December 11, 2018
HEALTHWEST Procedure No. 06-030 Prepared by: Effective Date: April 5, 2018 Revised Date: December 11, 2018 Cyndi Blair, RNBC Chief Clinical Officer Approved by: Subject: Vivitrol Administration Protocol
More informationOverview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone
Overview of Medication Assisted Treatment Methadone, Buprenorphine and Naltrexone Alexander Y. Walley, MD, MSc Associate Professor of Medicine Director, Addiction Medicine Fellowship Boston University
More informationAn Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women
An Adaptive Reinforcement-Based Treatment (RBT) Intervention for Pregnant Substance Dependent Women Michelle Tuten, Ph.D. Assistant Professor Department of Psychiatry and Behavioral Sciences and Johns
More informationReadopt with amendment Med 502, effective (Document #11090), to read as follows:
Adopted Rules 11-2-16 1 Readopt with amendment Med 502, effective 5-3-16 (Document #11090), to read as follows: PART Med 502 OPIOID PRESCRIBING Med 502.01 Applicability. This part shall apply to the prescribing
More informationProject Connections Buprenorphine Program
Project Connections Buprenorphine Program Program & Client Summary 2010-2017 Behavioral Health Leadership Institute November 2017 November 2017 1 Table of Contents I. Overview of the Project Connections
More informationIntegrated Dual Disorders Treatment (IDDT) Fidelity Scale Tips and Tools Treatment Characteristics and Organizational Characteristics
Tx.1a. Multidisciplinary Team: Case managers, psychiatrist, nurses, residential staff, and vocational specialists work collaboratively on mental health treatment team Tx.1b. Integrated Substance Abuse
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION RECOVERY-ORIENTED SYSTEMS OF CARE
ORGANIZATION OF AMERICAN STATES INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION FORTY-FOURTH REGULAR SESSION November 19-21, 2008 Santiago, Chile OEA/Ser.L/XIV.2.44 CICAD/doc.1687/08 13 November 2008 Original:
More informationHandbook for Postdoctoral Fellows at The Menninger Clinic
Handbook for Postdoctoral Fellows at The Menninger Clinic 2018-2019 Chris Fowler, PhD, director of Psychology Patricia Daza, PhD, director of Psychology Training 1 Overview The psychology discipline became
More informationTriage, Assessment and Treatment Planning
Triage, Assessment and Treatment Planning Prepared by Todd Sakakibara MD, CCFP, FCFP Clinical Assistant Professor, Dept. Family Practice UBC Diplomate of the American Board of Addiction Medicine Triage
More informationBuprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008
Buprenorphine: An Introduction Sharon Stancliff, MD Harm Reduction Coalition September 2008 Objective Participants will be able to: Discuss the role of opioid maintenance in reducing morbidity and mortality
More informationAMBULATORY DETOXIFICATION In the 21 st Century
AMBULATORY DETOXIFICATION In the 21 st Century Louis E. Baxter, Sr., M.D., DFASAM, DABAM DMHAS-Addiction Medicine Consultant Executive Medical Director Professional Assistance Program of N J Clinical Assistant
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationMedication-Assisted Treatment (MAT) Overview
Medication-Assisted Treatment (MAT) Overview 2014 Opiate Conference: Don t Get Me Started Hyatt Regency, Columbus, Ohio June 30-July 1, 2014 Christina M. Delos Reyes, MD Medical Consultant, Center for
More informationVivitrol Drug Court and Medication Assisted Treatment
Vivitrol Drug Court and Medication Assisted Treatment Amy Black, CNP and Judge Fred Moses Court program Self-starters Mission Statement To provide court-managed, medically assisted drug intervention treatment
More informationEffective Treatment: Doing the Right Thing, In the Right Way. Terrence D Walton, MSW, ICADC
Effective Treatment: Doing the Right Thing, In the Right Way Terrence D Walton, MSW, ICADC Monitor Manage Impact 1. Understand the Treatment Field, including Evidenced Based Practices 2. Understand Your
More informationUnderstanding and Combating the Heroin Epidemic
Understanding and Combating the Heroin Epidemic Kelly Dunn, Ph.D. Assistant Professor; Johns Hopkins School of Medicine Department of Psychiatry and Behavioral Sciences 1 Talk Outline What is causing the
More informationAddiction and Recovery Treatment Services (ARTS) Reimbursement Structure
Page 1 of 13 Billing Code Service Name Service Description ASAM Level APPROVED CODES & RATES APPROVED BY CENTERS FOR MEDICARE AND MEDICAID SERVICES AUGUST 25, 2017 Community Based Care Unit Lengths Annual
More informationPsychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence(review)
Cochrane Database of Systematic Reviews Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence(review) AmatoL,MinozziS,DavoliM,VecchiS
More informationHandbook for Postdoctoral Fellows at The Menninger Clinic
Handbook for Postdoctoral Fellows at The Menninger Clinic 2017-2018 Chris Fowler, Ph.D., director of Psychology Patricia Daza, PhD, director of Psychology Training 1 Overview The psychology discipline
More informationYouth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016
Youth, Opioid Use and Treatment Options CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016 Disclosures No propriety involvement in pharmaceutical companies Assessor, CPSO Methadone
More informationThe percentage of individuals admitted
Office-Based Buprenorphine Maintenance: Setting the Stage for Success Kenneth B. Stoller, MD; Van L. King, MD; Michael R. Clark, MD; Robert K. Brooner, PhD ABSTRACT PURPOSE: To review important principles
More informationHospitals Role in Addressing the Opioid Crisis
Hospitals Role in Addressing the Opioid Crisis Webinar 5: Buprenorphine in the Emergency Department November 14, 2017 Agenda Hospital Based Buprenorphine Initiatives Yngvild Olsen, M.D., Medical Consultant,
More informationMGH Substance Use Disorder Initiative. Dawn Williamson, RN, DNP, PMHCNS-BC, CARN-AP MGH ED Christopher Shaw, RN, ANP, PMHNP-BC, CARN-AP MGH ACT
Bridging the Gap: Bridging the Gaps to addiction treatment through comprehensive collaborative practice among Advanced Practice Nurses in a large urban Medical Center Dawn Williamson, RN, DNP, PMHCNS-BC,
More informationClinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More informationMedication Assisted Treatment. Nicole Gastala, MD
Medication Assisted Treatment Nicole Gastala, MD Objectives Training Goals: To enhance the understanding of the participants in use of medication assisted therapy To increase the knowledge of participants
More informationEffects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients
Blackwell Science, LtdOxford, UKADDAddiction1360-0443 2003 Society for the Study of Addiction to Alcohol and Other Drugs98665671Original ArticleContingency management and desipramine for cocaine Thomas
More informationThe Opioid Crisis: What Can Physicians Do About It?
The Opioid Crisis: What Can Physicians Do About It? Richard S. Schottenfeld, M.D. Professor and Chair, Department of Psychiatry and Behavioral Sciences 2018 Louis J. Kolodner Memorial Lecture Disclosures
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationNote: The trainings below represent a foundational list, and may be adapted based on audience and need.
MOTIVATIONAL INTERVIEWING Introduction to Motivational Interviewing (offered in English and Spanish) 2-day Course (12-14 credit hours) This course is designed to introduce clinicians and staff members
More informationHEALTHWEST. Procedure. No Prepared by: Effective Date: June 1, 2017 Revised Date: November 13, 2018 Cyndi Blair, RNBC Chief Clinical Officer
HEALTHWEST Procedure No. 06-031 Prepared by: Effective Date: June 1, 2017 Revised Date: November 13, 2018 Cyndi Blair, RNBC Chief Clinical Officer Approved by: Subject: Suboxone (Buprenorphine, Naloxone,
More informationVivitrol Vs. Suboxone
Vivitrol Vs. Suboxone Vivitrol - Naltrexone Indicated for opiate dependence and alcohol withdrawal pure antagonist 380mg once every 4 weeks IM Peak plasma concentration in 2 hrs, followed by a second peak
More informationBASIC VOLUME. Elements of Drug Dependence Treatment
BASIC VOLUME Elements of Drug Dependence Treatment Module 3 Principles of CBT and relapse prevention strategies Introduction to Cognitive Behavioural Therapy Basics of pharmacological treatment Workshop
More informationNIDA Principles of Treatment. NIDA Principles of Treatment. Peter Banys, M.D., M.Sc. No single treatment is appropriate for all individuals.
NIDA Principles of Treatment Peter Banys, M.D., M.Sc. CSAM Addiction Medicine Review Course San Francisco October 5 th, 2006 NIDA Principles of Treatment 1. Treatment Matching 2. Availability 3. Domains
More informationOUTPATIENT TREATMENT WESTPORT, CONNECTICUT
OUTPATIENT TREATMENT WESTPORT, CONNECTICUT ABOUT CLEARPOINT At Clearpoint, we focus on healing the whole person: mind, body, and spirit. Our comprehensive care methods set clients up for long-term success
More informationNote: The trainings below represent a foundational list, and may be adapted based on audience and need.
MOTIVATIONAL INTERVIEWING Introduction to Motivational Interviewing (offered in English and Spanish) 2-day Course (12-14 credit hours) This course is designed to introduce clinicians and staff members
More informationJohn Murphy DO, MS Lynx Healthcare
Addiction to Pain Medication and Treatment John Murphy DO, MS Lynx Healthcare No Disclosures Objectives 1 Understand basic neurobiology and learning theory around opioid addiction 2 Identify aberrant behavior
More information